Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF in Newly Diagnosed MGMT-Methylated Glioblastoma
NCT06649851Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2025
- Primary completion
- Jan 2027
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of granulocyte colony-stimulating factor in glioblastoma (GBM) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Incidence of adverse events up to 35 weeks and Change in Brain Volume from Baseline up to 62 weeks. Started Apr 2025; status: recruiting.
02
Drugs
granulocyte colony-stimulating factor
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06649851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649851.